



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS WASHINGTON, DC 20231 www.uspto.gov

APPLICATION NO). F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO.
09/944,497	•	08/31/2001	Mohan Ramachandra Wani	A34628; 066123.0109	2639
21003	7590	03/25/2003			
	& BOTTS		EXAMINER		
	EFELLER F RK, NY - 10			WINSTON, RANDALL	ANDALL O
				ART UNIT	PAPER NUMBER
				1654	
				DATE MAILED: 03/25/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/944,497

Applicant(s)

Ramachandra et al.

Examiner

Randall Winston

Art Unit 1654



	The MAILING DATE of this communication appears of	on the cover sheet with the correspondence address
Period f	for Reply	
THE	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	
	ions of time may be available under the provisions of 37 CFR 1.136 (a). In r I date of this communication.	no event, however, may a reply be timely filed after SIX (6) MONTHS from the
· If NO p - Failure - Any re	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply and to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	nd will expire SIX (6) MONTHS from the mailing date of this communication. e application to become ABANDONED (35 U.S.C. § 133).
Status		
1)	Responsive to communication(s) filed on	
2a)	This action is FINAL . $2b) \widetilde{\mathbf{X}}$ This action	on is non-final.
3) 🗀	Since this application is in condition for allowance e closed in accordance with the practice under Ex par	except for formal matters, prosecution as to the merits is attention of the Augustian Care Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposi	tion of Claims	
4) X	Claim(s) <u>1-35</u>	is/are pending in the application.
4	la) Of the above, claim(s) <u>1-8 and 31-35</u>	is/are withdrawn from consideration.
5)	Claim(s)	is/are allowed.
6) X	Claim(s) 9-30	is/are rejected.
7)	Claim(s)	is/are objected to.
8) 📖	Claims	are subject to restriction and/or election requirement.
	ition Papers	
9)	The specification is objected to by the Examiner.	
10) =	The drawing(s) filed on is/are	a) accepted or b) objected to by the Examiner.
	Applicant may not request that any objection to the di	rawing(s) be held in abeyance. See 37 CFR 1.85(a).
11)	The proposed drawing correction filed on	is. a) approved b) disapproved by the Examiner.
	If approved, corrected drawings are required in reply t	
12) 🗔	The oath or declaration is objected to by the Examin	ner.
Priority	under 35 U.S.C. §§ 119 and 120	
13)	Acknowledgement is made of a claim for foreign pr	iority under 35 U.S.C. § 119(a)-(d) or (f).
a) [All b) Some* c) None of:	
	1. Certified copies of the priority documents have	e been received.
	2. Certified copies of the priority documents have	e been received in Application No
	3. Copies of the certified copies of the priority do application from the International Burea	
*S	ee the attached detailed Office action for a list of the	e certified copies not received.
14)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).
a)	The translation of the foreign language provisiona	-
15)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.
Attachm		
	otice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).
	otice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)
3) Inf	formation Disclosure Statement(s) (PTO-1449) Paper No(s)	6) Other:

Application/Control Number: 09/944,497 Page 2

Art Unit: 1654

DETAILED ACTION

Election/Restriction

Applicants' election with traverse of Group III, Claims 9-20 in Paper No. 5 is acknowledged. The traversal is on the grounds that the applicants argue that Groups III and IV are not sufficiently independent and distinct so as to require restriction in the present case. Applicants' argument is found persuasive, thus, Group III and IV will be rejoined. Furthermore, because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement for Group I, II and V, the election has been treated as an election without traverse (MPEP § 818.03(a)). Claims 9-30 will be examined on the merits.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 9-30 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 9, 19, 20, 21, 26, 27 are rendered vague and indefinite by the term "mussel hydrolysate" because this term, in and of itself, does not adequately delineate its metes and bounds. This term is best defined as a product-by-process since product-by-process claims are intended to define products which are otherwise difficult to define (and/or distinguish from the

Application/Control Number: 09/944,497 Page 3

Art Unit: 1654

prior art). For example, is the mussel hydrolysate obtained via extraction with water, a polar solvent, a non-polar solvent, and acid or base, a squeezed extract, or something else? It is well accepted in the art that extraction with one of various distinct solvents, has a profound impact on the final product with respect to the presence, absence, amounts, and/or ratios of active ingredients therein and, thus, its ability to provide the desired functional effect(s) instantly claimed and/or disclosed. Since the mussel hydrolysate itself is clearly essential to the claimed invention, the step(s) by which the claimed mussel hydrolysate is obtained are also clearly essential and, therefore, must be recited in the claim language itself(i.e., as a product-by-process). Please note that although the claims are interpreted in light of the specification, critical limitations from the specification cannot read into the claims(see, e.g., In re Van Guens, 988 F.2d 1181, 26 PSPG2d 1057 (Ded. Cir. 1991)). Accordingly, without the recitation of all these critical limitations as set forth above, the claims do not adequately define the instant invention. Therefore, it is strongly suggested that applicant may overcome this rejection by clearly defining what type of an extract is an "extract of mussel hydrolysate from Indian green mussel "being utilized (please see, specification page 8-10 for product by process guidance).

Claims 9 and 21 are rendered vague and indefinite because they fail to recite any operative amount of the claimed mussel hydrolysate ingredient. Therefore, it is unclear if the mussel hydrolysate ingredient is an active agent within the composition, if it is merely some type of inert agent, and/or if it is present in very small amounts representing perhaps a contaminant or residue. The claimed mussel hydrolysate is deemed to be essential elements of the invention and,

Application/Control Number: 09/944,497 Page 4

Art Unit: 1654

as such, they should be clearly defined (functionally) in the claim language itself. Accordingly, it is suggested that the phrase--biologically effective amounts-- be inserted after the word "comprising" (Claim 9 line 2 and claim 21 line 2) or, alternatively, that the limitations recited in claims 19 and 20 be appropriately incorporated into claim 9 and the limitations recited in claims 26 and 27 be appropriately incorporated into claim 21 to clarify this ambiguity.

All other claims depend directly or indirectly from rejected claims and are, therefore, also rejected under 35 U.S.C. 112, second paragraph for the reasons set forth above.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Randall Winston whose telephone number is (703) 305-0404. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196 or the Supervisory Patent Examiner, Brenda Brumback whose telephone number is (703) 306-3220.

row

CHRISTOPHER R. TATE PRIMARY EXAMINER